APA (7th ed.) Citation

M, I., T, Y., Y, K., H, K., R, S., R, N., . . . K, T. (2026). AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1), . https://doi.org/10.1038/s41698-026-01385-2

Chicago Style (17th ed.) Citation

M, Ishida, et al. "AXL-SHC1 Signaling Axis Mediates Adaptive Resistance to HER2-targeted Tyrosine Kinase Inhibitors in HER2-aberrant Lung and Gastric Cancers." NPJ Precision Oncology 10, no. 1 (2026). https://doi.org/10.1038/s41698-026-01385-2.

MLA (9th ed.) Citation

M, Ishida, et al. "AXL-SHC1 Signaling Axis Mediates Adaptive Resistance to HER2-targeted Tyrosine Kinase Inhibitors in HER2-aberrant Lung and Gastric Cancers." NPJ Precision Oncology, vol. 10, no. 1, 2026, https://doi.org/10.1038/s41698-026-01385-2.